Article List
List all articles in the database by earliest discovery_date
GET /articles/?format=api&page=1347
{ "count": 24462, "next": "http://api.gregory-ms.com/articles/?format=api&page=1348", "previous": "http://api.gregory-ms.com/articles/?format=api&page=1346", "results": [ { "article_id": 439634, "title": "Autoimmune hepatitis and multiple sclerosis: a coincidental association?", "summary": "<jats:p> In the present study we report, as part of a large multiple sclerosis (MS) cohort (1800 patients), three cases of untreated patients who developed autoimmune hepatitis (AIH). The prevalence of AIH in the general population is about 0.0169% and seems to be higher in our MS cohort (0.17%). We suggest that a liver biopsy should systematically be performed in untreated MS patients with a sustained increase of liver enzyme. </jats:p>", "link": "https://journals.sagepub.com/doi/pdf/10.1191/1352458505ms1239oa", "published_date": "2005-12-01T00:00:00Z", "source": "SAGE Publications", "publisher": "SAGE Publications", "container_title": "Multiple Sclerosis Journal", "authors": [ { "author_id": 267331, "given_name": "J", "family_name": "de Seze", "ORCID": null, "country": null }, { "author_id": 290993, "given_name": "V", "family_name": "Canva-Delcambre", "ORCID": null, "country": null }, { "author_id": 277749, "given_name": "I", "family_name": "Fajardy", "ORCID": null, "country": null }, { "author_id": 290995, "given_name": "S", "family_name": "Delalande", "ORCID": null, "country": null }, { "author_id": 267337, "given_name": "T", "family_name": "Stojkovic", "ORCID": null, "country": null }, { "author_id": 290997, "given_name": "E", "family_name": "Godet", "ORCID": null, "country": null }, { "author_id": 250464, "given_name": "P", "family_name": "Vermersch", "ORCID": null, "country": null } ], "relevant": null, "ml_prediction_gnb": false, "ml_prediction_lr": false, "ml_prediction_lsvc": false, "discovery_date": "2022-06-09T10:40:10.361319Z", "noun_phrases": [ "Autoimmune hepatitis and multiple sclerosis: a coincidental association" ], "doi": "10.1191/1352458505ms1239oa", "access": "restricted", "takeaways": " Three cases of untreated MS patients developed autoimmune hepatitis (AIH) The prevalence of AIH in the general population is about 0.0169% and seems", "categories": [] }, { "article_id": 439633, "title": "The initial course of daily functioning in multiple sclerosis: a three-year follow-up study", "summary": "<jats:p> We studied the initial course of daily functioning in multiple sclerosis (MS). A cohort of 156 recently diagnosed patients was prospectively followed for three years (five measurements). Domains of interest were neurological deficits, physical functioning, mental health, social functioning and general health. An a priori distinction was made between a relapse onset group (n=128) and a non-relapse onset group (n=28). At baseline, neurological deficits are relatively minor for most patients, 26.3% have aberrant physical functioning scores, 38.5% have aberrant social functioning scores, 9% have aberrant mental health scores and 25% have aberrant general health scores. The neurological deficits and physical functioning deteriorated significantly over time. This deterioration was more pronounced and clinically relevant in the non-relapse onset group only. Mental health showed a significant, but not clinically relevant deterioration over time. Social functioning and general health showed non-significant effects for time. It is concluded that in the initial stage of MS, when neurological deficits are relatively minor and mental health is relatively unaffected, patients in both groups experience limitations in daily functioning. Patients in the non-relapse onset group have progressive neurological symptoms that are accompanied by progressive limitations in physical functioning, but not by progressive limitations in the other domains. </jats:p>", "link": "https://journals.sagepub.com/doi/pdf/10.1191/1352458505ms1238oa", "published_date": "2005-12-01T00:00:00Z", "source": "SAGE Publications", "publisher": "SAGE Publications", "container_title": "Multiple Sclerosis Journal", "authors": [ { "author_id": 256607, "given_name": "V", "family_name": "de Groot", "ORCID": null, "country": null }, { "author_id": 256609, "given_name": "H", "family_name": "Beckerman", "ORCID": null, "country": null }, { "author_id": 267065, "given_name": "G J", "family_name": "Lankhorst", "ORCID": null, "country": null }, { "author_id": 242183, "given_name": "C H", "family_name": "Polman", "ORCID": null, "country": null }, { "author_id": 267067, "given_name": "L M", "family_name": "Bouter", "ORCID": null, "country": null } ], "relevant": null, "ml_prediction_gnb": false, "ml_prediction_lr": false, "ml_prediction_lsvc": false, "discovery_date": "2022-06-09T10:40:10.360468Z", "noun_phrases": [ "The initial course", "multiple sclerosis", "a three-year follow-up study" ], "doi": "10.1191/1352458505ms1238oa", "access": "open", "takeaways": " We studied the initial course of daily functioning in multiple sclerosis (MS) A cohort of 156 recently diagnosed patients was prospectively followed for three years . Domains of interest were neurological deficits, physical functioning, mental health, social functioning and general health . Neurological deficits and physical functioning deteriorated significantly over time .", "categories": [] }, { "article_id": 439632, "title": "Conservative bladder management in advanced multiple sclerosis", "summary": "<jats:p> Anticholinergics and intermittent catheterization are the cornerstones of bladder management in early multiple sclerosis (MS). In advanced MS however, bladder management is based more on tradition than on evidence. Nurses seem to deal with catheter problems and chronic incontinence. Despite the abundant use of indwelling catheters, there is a lack for guidelines on catheter-induced problems. The psychosexual and social impact of bladder problems in advanced MS is often neglected. The international multidisciplinary special interest group on sexual, urological and bowel dysfunction in MS (SUBDIMS) as a special interest group of the Rehabilitation in Multiple Sclerosis (RIMS) was confronted with a high variability in practice and a lack of guidelines. A literature review was prepared during three multidisciplinary expert meetings. This review will be the basis of further initiatives to improve the urological treatment of patients with advanced MS. </jats:p>", "link": "https://journals.sagepub.com/doi/pdf/10.1191/1352458505ms1237oa", "published_date": "2005-12-01T00:00:00Z", "source": "SAGE Publications", "publisher": "SAGE Publications", "container_title": "Multiple Sclerosis Journal", "authors": [ { "author_id": 304712, "given_name": "D", "family_name": "De Ridder", "ORCID": null, "country": null }, { "author_id": 304713, "given_name": "D", "family_name": "Ost", "ORCID": null, "country": null }, { "author_id": 304714, "given_name": "F", "family_name": "Van der Aa", "ORCID": null, "country": null }, { "author_id": 304715, "given_name": "M", "family_name": "Stagnaro", "ORCID": null, "country": null }, { "author_id": 304716, "given_name": "C", "family_name": "Beneton", "ORCID": null, "country": null }, { "author_id": 295871, "given_name": "K", "family_name": "Gross-Paju", "ORCID": null, "country": null }, { "author_id": 304717, "given_name": "P", "family_name": "Eelen", "ORCID": null, "country": null }, { "author_id": 304718, "given_name": "H", "family_name": "Limbourg", "ORCID": null, "country": null }, { "author_id": 304719, "given_name": "M", "family_name": "Harper", "ORCID": null, "country": null }, { "author_id": 304720, "given_name": "J C", "family_name": "Segal", "ORCID": null, "country": null }, { "author_id": 254291, "given_name": "C J", "family_name": "Fowler", "ORCID": null, "country": null }, { "author_id": 304721, "given_name": "A", "family_name": "Nordenbo", "ORCID": null, "country": null } ], "relevant": null, "ml_prediction_gnb": false, "ml_prediction_lr": false, "ml_prediction_lsvc": false, "discovery_date": "2022-06-09T10:40:10.359615Z", "noun_phrases": [ "Conservative bladder management", "advanced multiple sclerosis" ], "doi": "10.1191/1352458505ms1237oa", "access": "restricted", "takeaways": " Anticholinergics and intermittent catheterization are cornerstones of bladder management in early MS . In advanced MS however, bladder management is based more on tradition than on evidence . Nurses seem to deal with catheter problems and chronic incontinence .", "categories": [] }, { "article_id": 439631, "title": "Measuring quality of life in multiple sclerosis: not as simple as it sounds", "summary": "<jats:p> Data from a clinical study presented an opportunity to examine the psychometric properties of the Leeds Multiple Sclerosis Quality of Life scale (LMSQoL), which has undergone limited psychometric evaluation. LMSQoL and Multiple Sclerosis Quality of Life-54 (MSQoL-54) data were collected from 90 people with multiple sclerosis (MS) living in the community. Standard psychometric methods to examine data quality, scaling assumptions, scale to sample targeting, reliability, validity, and responsiveness were employed. The LMSQoL satisfied criteria for data quality (no missing data), scaling assumptions (item-total correlations: 0.24-0.56), reliability (Cronbach’s alpha: 0.71), and demonstrated responsiveness (effect size: 0.34). Correlations between the LMSQoL and MSQoL-54 physical (range:-0.02 to-0.50) and emotional subscales (range:-0.38 to-0.65) were similar; the magnitude and pattern was not consistent with predictions based on the construct purported to be measured by the LMSQoL. The LMSQoL satisfied many psychometric criteria in this small study, however, it was difficult to interpret the validity data. From this, two fundamental measurement issues are highlighted. Firstly, current methods of examining rating scales provide only circumstantial evidence of validity; secondly, health-rating scales should be developed on the basis of clear conceptual definitions. </jats:p>", "link": "https://journals.sagepub.com/doi/pdf/10.1191/1352458505ms1235oa", "published_date": "2005-12-01T00:00:00Z", "source": "SAGE Publications", "publisher": "SAGE Publications", "container_title": "Multiple Sclerosis Journal", "authors": [ { "author_id": 289654, "given_name": "L", "family_name": "Nicholl", "ORCID": null, "country": null }, { "author_id": 292481, "given_name": "J C", "family_name": "Hobart", "ORCID": null, "country": null }, { "author_id": 304261, "given_name": "A FL", "family_name": "Cramp", "ORCID": null, "country": null }, { "author_id": 304262, "given_name": "A S", "family_name": "Lowe-Strong", "ORCID": null, "country": null } ], "relevant": null, "ml_prediction_gnb": false, "ml_prediction_lr": false, "ml_prediction_lsvc": false, "discovery_date": "2022-06-09T10:40:10.358610Z", "noun_phrases": [ "quality", "life", "multiple sclerosis", "it" ], "doi": "10.1191/1352458505ms1235oa", "access": "restricted", "takeaways": " Leeds Multiple Sclerosis Quality of Life scale (LMSQoL) satisfied criteria for data quality (no missing data), scaling assumptions (item-total correlations: 0.24-0.56), reliability (Cronbach’s alpha) and demonstrated responsiveness (effect size): 0.34) Correlations between the LMSQOL and MSQoOL-54 physical (range:-0.02 to-0", "categories": [] }, { "article_id": 439630, "title": "Axonal metabolic recovery and potential neuroprotective effect of glatiramer acetate in relapsing-remitting multiple sclerosis", "summary": "<jats:p> Glatiramer acetate (GA) is a disease-modifying therapy for relapsing-remitting multiple sclerosis (RRMS) with several putative mechanisms of action. Currently, there is paucity ofin vivo human data linking the well-established peripheral immunologic effects of therapy with GA to its potential effects inside the central nervous system (CNS). Brain proton magnetic resonance spectroscopy (MRS) allows in vivo examination of axonal integrity by quantifying the resonance intensity of the neuronal marker N-acetylaspartate (NAA). In a pilot study to investigate the effect of GA on axonal injury, we performed combined brain magnetic resonance imaging (MRI) and MRS studies in 18 treatment naïve RRMS patients initiating therapy with GA at baseline and annually for two years on therapy. A small group of four treatment naïve RRMS patients, electing to remain untreated, served as controls. NAA/Cr was measured in a large central brain volume of interest (VOI) as well as the normal appearing white matter (NAWM) within the VOI. After two years, NAA/Cr in the GA-treated group increased significantly by 10.7% in the VOI (2.179±0.26 versus 1.969±0.24, P=0.03) and by 7.1% in the NAWM (2.239±0.26 versus 2.089±0.31, P=0.04). In the untreated group, NAA/Cr decreased by 8.9% at two years in the VOI (2.019±0.16 versus 1.839±0.21, P=0.03) and 8.2% in the NAWM (2.079±0.24 versus 1.909±0.29, P=0.03). Our data shows that treatment with GA leads to axonal metabolic recovery and protection from sub-lethal axonal injury. These results support an in situ effect of GA therapy inside the CNS and suggest potential neuroprotective effects of GA. </jats:p>", "link": "https://journals.sagepub.com/doi/pdf/10.1191/1352458505ms1234oa", "published_date": "2005-12-01T00:00:00Z", "source": "SAGE Publications", "publisher": "SAGE Publications", "container_title": "Multiple Sclerosis Journal", "authors": [ { "author_id": 244105, "given_name": "Omar", "family_name": "Khan", "ORCID": null, "country": null }, { "author_id": 244107, "given_name": "Yimin", "family_name": "Shen", "ORCID": null, "country": null }, { "author_id": 244108, "given_name": "Christina", "family_name": "Caon", "ORCID": null, "country": null }, { "author_id": 244109, "given_name": "F en", "family_name": "Bao", "ORCID": null, "country": null }, { "author_id": 244111, "given_name": "Wendy", "family_name": "Ching", "ORCID": null, "country": null }, { "author_id": 244112, "given_name": "Melissa", "family_name": "Reznar", "ORCID": null, "country": null }, { "author_id": 244113, "given_name": "Alyssa", "family_name": "Buccheister", "ORCID": null, "country": null }, { "author_id": 244114, "given_name": "Jiani", "family_name": "Hu", "ORCID": null, "country": null }, { "author_id": 244116, "given_name": "Zahid", "family_name": "Latif", "ORCID": null, "country": null }, { "author_id": 244117, "given_name": "Alexandros", "family_name": "Tselis", "ORCID": null, "country": null }, { "author_id": 244118, "given_name": "Robert", "family_name": "Lisak", "ORCID": null, "country": null } ], "relevant": null, "ml_prediction_gnb": false, "ml_prediction_lr": false, "ml_prediction_lsvc": false, "discovery_date": "2022-06-09T10:40:10.357733Z", "noun_phrases": [ "Axonal metabolic recovery", "potential neuroprotective effect", "glatiramer acetate", "relapsing-remitting multiple sclerosis" ], "doi": "10.1191/1352458505ms1234oa", "access": "restricted", "takeaways": " Glatiramer acetate (GA) is a disease-modifying therapy for relapsing-remitting multiple sclerosis . There is paucity ofin vivo human data linking the well-established immunologic effects of therapy with GA to its potential effects inside the central nervous system . Brain proton magnetic resonance spectroscopy allows in vivo examination of axonal integrity by quantifying the resonance intensity of the neuronal marker N-acetylaspartate (NAA)", "categories": [] }, { "article_id": 439629, "title": "The future of multiple sclerosis therapies: redesigning multiple sclerosis clinical trials in a new therapeutic eraa", "summary": "<jats:p> Due to past success in testing and gaining regulatory approval for a variety of therapies in multiple sclerosis (MS), the conduct of future clinical trials has become increasingly problematic. An international workshop has met to discuss the issues facing the MS clinical trial community and to examine possible new strategies for the design of trials. Particular focus has been placed on trials that either avoid the use of a placebo because of ethical considerations or on designs that allow new therapies to be studied more rapidly or with fewer patients than needed in a conventional placebo-controlled trial. The discussions resulting from the workshop should provide a basis for the examination and implementation of innovative clinical trial designs in MS. </jats:p>", "link": "https://journals.sagepub.com/doi/pdf/10.1191/1352458505ms1231oa", "published_date": "2005-12-01T00:00:00Z", "source": "SAGE Publications", "publisher": "SAGE Publications", "container_title": "Multiple Sclerosis Journal", "authors": [ { "author_id": 256825, "given_name": "H F", "family_name": "McFarland", "ORCID": null, "country": null }, { "author_id": 259781, "given_name": "S C", "family_name": "Reingold", "ORCID": null, "country": null } ], "relevant": null, "ml_prediction_gnb": false, "ml_prediction_lr": false, "ml_prediction_lsvc": false, "discovery_date": "2022-06-09T10:40:10.356365Z", "noun_phrases": [ "The future", "multiple sclerosis therapies", "multiple sclerosis clinical trials", "a new therapeutic eraa" ], "doi": "10.1191/1352458505ms1231oa", "access": "restricted", "takeaways": " An international workshop has met to discuss the issues facing the MS clinical trial community . Particular focus has been placed on trials that either avoid the use of a placebo because of ethical considerations or on designs that allow new therapies to be studied more rapidly .", "categories": [] }, { "article_id": 439628, "title": "Interferon-beta-1b effects on re-enhancing lesions in patients with multiple sclerosis", "summary": "<jats:p> Interferon-beta (IFNβ) reduces the number and load of new contrast-enhancing lesions (CELs) in patients with multiple sclerosis (MS). However, the ability of IFNβ to reduce lesion sizes and re-enhancements of pre-existing CELs has not been examined extensively. Activity of contrast re-enhancing lesions (Re-CELs) and contrast single-enhancing lesions (S-CELs) were monitored in ten patients with relapsingremitting (RR) MS. These patients underwent monthly post-contrast magnetic resonance imaging (MRIs) for an 18-month natural history phase and an 18-month therapy phase with subcutaneous IFNβ-1b, totaling 37 images per patient. The activity was analysed using the first image as a baseline and registering subsequent active monthly images to the baseline. There was a 76.4% reduction in the number of CELs with IFNβ therapy. The decrease was greater (P=0.003) for S-CELs (82.3%) than for Re-CELs (57.4%). S-CELs showed no changes in durations of enhancement and maximal lesion sizes with treatment. Exclusively for Re-CELs, IFNβ-1b significantly decreased maximal lesion sizes, total number of enhancement periods and total months of enhancement. Thus, IFNβ appears to be effective in reducing the degree of severity of inflammation among Re-CELs, as reflected by their reduced maximal lesion sizes and durations of enhancement. </jats:p>", "link": "https://journals.sagepub.com/doi/pdf/10.1191/1352458505ms1229oa", "published_date": "2005-12-01T00:00:00Z", "source": "SAGE Publications", "publisher": "SAGE Publications", "container_title": "Multiple Sclerosis Journal", "authors": [ { "author_id": 265786, "given_name": "S", "family_name": "Gupta", "ORCID": null, "country": null }, { "author_id": 265787, "given_name": "J M", "family_name": "Solomon", "ORCID": null, "country": null }, { "author_id": 265788, "given_name": "T A", "family_name": "Tasciyan", "ORCID": null, "country": null }, { "author_id": 265789, "given_name": "M M", "family_name": "Cao", "ORCID": null, "country": null }, { "author_id": 265790, "given_name": "R D", "family_name": "Stone", "ORCID": null, "country": null }, { "author_id": 265791, "given_name": "J L", "family_name": "Ostuni", "ORCID": null, "country": null }, { "author_id": 265792, "given_name": "J M", "family_name": "Ohayon", "ORCID": null, "country": null }, { "author_id": 265793, "given_name": "P A", "family_name": "Muraro", "ORCID": null, "country": null }, { "author_id": 256823, "given_name": "J A", "family_name": "Frank", "ORCID": null, "country": null }, { "author_id": 256822, "given_name": "N D", "family_name": "Richert", "ORCID": null, "country": null }, { "author_id": 256825, "given_name": "H F", "family_name": "McFarland", "ORCID": null, "country": null }, { "author_id": 265794, "given_name": "F", "family_name": "Bagnato", "ORCID": null, "country": null } ], "relevant": null, "ml_prediction_gnb": false, "ml_prediction_lr": false, "ml_prediction_lsvc": false, "discovery_date": "2022-06-09T10:40:10.355210Z", "noun_phrases": [ "Interferon-beta-1b effects", "re", "-enhancing lesions", "patients", "multiple sclerosis" ], "doi": "10.1191/1352458505ms1229oa", "access": "restricted", "takeaways": " Interferon-beta (IFNβ) reduces the number and load of new contrast-enhancing lesions (CELs) in patients with multiple sclerosis . The ability of IFNβ to reduce lesion sizes and re-enhancements of pre-existing CELs has not been examined extensively .", "categories": [] }, { "article_id": 439627, "title": "Prognostic factors in multidisciplinary rehabilitation treatment in multiple sclerosis: an outcome study", "summary": "<jats:p> The aim of this outcome study was to evaluate the effectiveness and prognostic factors of inpatient multidisciplinary rehabilitation treatment in patients with multiple sclerosis (MS). We analysed 230 consecutive inpatients with MS admitted to an MS rehabilitation ward who followed an individualized, goal-oriented, multidisciplinary rehabilitation program. Every patient was submitted to a neurological examination and evaluated by means of Kurtzke’s Expanded Disability Status Scale (EDSS), with its functional systems (FS), Barthel Index (BI) and the Rivermead Mobility Index (RMI). We observed an effectiveness (percentage of potential improvement achieved during rehabilitation) of nearly 16% on BI and 8% on RMI, corresponding to an improvement in 124 patients (54%) on BI and 113 patients (49%) on RMI. Basal EDSS (β= -0.32, p<0.001), cognitive status (β= -0.15, p<0.05) and disease duration (β= -0.13, p<0.05) were negatively associated with effectiveness of treatment on BI (adjusted R<jats:sup>2</jats:sup>=0.176), whereas effectiveness on RMI was correlated only with the EDSS score (β=-0.34, p<0.001, adjusted R<jats:sup>2</jats:sup>=0.113). In the logistic regression analysis, the absence of severe sphincteric disturbances was correlated with the probability of improvement on BI that was nearly twice as high (OR=2.25, 95% CI 1.24-4.08) as that of other patients. Moreover, patients without severe cognitive deficits showed a similar probability (OR-2.37, 95% CI 1.05-5.33) of improvement on RMI. The results of this study provide further evidence that intensive multidisciplinary rehabilitation in MS is effective in the majority of MS patients and that early treatment may favour functional recovery. </jats:p>", "link": "https://journals.sagepub.com/doi/pdf/10.1191/1352458505ms1226oa", "published_date": "2005-12-01T00:00:00Z", "source": "SAGE Publications", "publisher": "SAGE Publications", "container_title": "Multiple Sclerosis Journal", "authors": [ { "author_id": 285715, "given_name": "M G", "family_name": "Grasso", "ORCID": null, "country": null }, { "author_id": 268188, "given_name": "E", "family_name": "Troisi", "ORCID": null, "country": null }, { "author_id": 294478, "given_name": "F", "family_name": "Rizzi", "ORCID": null, "country": null }, { "author_id": 294479, "given_name": "D", "family_name": "Morelli", "ORCID": null, "country": null }, { "author_id": 294480, "given_name": "S", "family_name": "Paolucci", "ORCID": null, "country": null } ], "relevant": null, "ml_prediction_gnb": false, "ml_prediction_lr": false, "ml_prediction_lsvc": false, "discovery_date": "2022-06-09T10:40:10.354100Z", "noun_phrases": [ "Prognostic factors", "multidisciplinary rehabilitation treatment", "multiple sclerosis", ": an outcome study" ], "doi": "10.1191/1352458505ms1226oa", "access": "restricted", "takeaways": " The aim of this outcome study was to evaluate the effectiveness and prognostic factors of inpatient multidisciplinary rehabilitation treatment in patients with multiple sclerosis . We observed an effectiveness (percentage of potential improvement achieved during rehabilitation) of nearly 16% on BI and 8% on RMI .", "categories": [] }, { "article_id": 439626, "title": "Suppression of acute experimental allergic encephalomyelitis with a small molecule inhibitor of α4 integrin", "summary": "<jats:p> Purpose: To determine the efficacy of a small molecule inhibitor of α<jats:sub>4</jats:sub> integrin (CT301) at reversing the clinical, pathological and MR- detectable deficits associated with the acute phase of experimental allergic encephalomyelitis (EAE). Materials and methods: EAE was induced in 36 female Hartley guinea pigs, and the treatment period was from day 11 to day 17 post-immunization. Animals received either saline (n=12), anti-α<jats:sub>4</jats:sub> integrin antibody (AN100226m; n=12) or CT301 (n=12). T2-weighted fast spin echo and T1-weighted pre- and post-contrast scans were performed at the beginning (day 11) and end (day 18) of the treatment period, and scored for cerebral inflammation and gadolinium enhancement. T1-weighted images were further analyzed to quantify this enhancement as a measure of blood-brain barrier integrity. Dissected CNS was evaluated for inflammation and demyelination. Results: CT301 successfully reversed two clinical indicators of disease over the course of the treatment period. These animals showed decreased T2-weighted abnormalities, as well as a reduction in gadolinium leakage on T1-weighted images. Meningeal and perivascular inflammation was decreased by anti-α<jats:sub>4</jats:sub> integrin treatments. Conclusion: CT301 effectively reverses the clinical, pathological and MR-detectable deficits of acute EAE, and may therefore be a promising therapeutic agent in multiple sclerosis (MS). </jats:p>", "link": "https://journals.sagepub.com/doi/pdf/10.1191/1352458505ms1223oa", "published_date": "2005-12-01T00:00:00Z", "source": "SAGE Publications", "publisher": "SAGE Publications", "container_title": "Multiple Sclerosis Journal", "authors": [ { "author_id": 309308, "given_name": "P S", "family_name": "Piraino", "ORCID": null, "country": null }, { "author_id": 309309, "given_name": "T A", "family_name": "Yednock", "ORCID": null, "country": null }, { "author_id": 309310, "given_name": "S B", "family_name": "Freedman", "ORCID": null, "country": null }, { "author_id": 309311, "given_name": "E K", "family_name": "Messersmith", "ORCID": null, "country": null }, { "author_id": 309312, "given_name": "M A", "family_name": "Pleiss", "ORCID": null, "country": null }, { "author_id": 296257, "given_name": "S J", "family_name": "Karlik", "ORCID": null, "country": null } ], "relevant": null, "ml_prediction_gnb": false, "ml_prediction_lr": false, "ml_prediction_lsvc": false, "discovery_date": "2022-06-09T10:40:10.352830Z", "noun_phrases": [ "Suppression", "acute experimental allergic encephalomyelitis", "a small molecule inhibitor", "α4 integrin" ], "doi": "10.1191/1352458505ms1223oa", "access": "restricted", "takeaways": " EAE was induced in 36 female Hartley guinea pigs . Animals received either saline (n=12), anti-α4 integrin antibody (AN100226m) or CT301 . CT301 successfully reversed two clinical indicators of disease over the course of the treatment period .", "categories": [] }, { "article_id": 439625, "title": "Upregulation of TRAIL expression on human T lymphocytes by interferon b and glatiramer acetate", "summary": "<jats:p> We measured the in vivo and in vitro effects of interferon (IFN)b and glatiramer acetate (GA) on the expression of the regulatory molecule, tumor necrosis factor related apoptosis inducing ligand (TRAIL), in patients with multiple sclerosis (MS). We confirmed the prior observation that TRAIL is enhanced on anti-CD3 activated T cells by the in vitro addition of IFNβ. T cells from IFNβ-treated patients stimulated with anti-CD3 only, had higher levels of TRAIL than untreated patients, suggesting that in vivo IFNβ exposure has an effect on TRAIL expression in association with T cell activation. In vitro IFNβ-induced TRAIL upregulation on anti-CD3 or phytohemagglutinin-activated T cells was comparable for IFNβ-treated and non-treated MS patients and controls, indicating that IFN receptors were neither saturated nor down-regulated by current IFNβ therapy. Although GAin vivo orin vitro did not induce TRAIL, the IFNβ-GA combination in vitro enhanced TRAIL expression to higher levels than IFNβ alone on CD4+ T cells obtained from MS patients, regardless of GA treatment status, and healthy donors, and on GA reactive T cell lines derived from GA-treated patients or controls. Whether any observed therapeutic effects of GA/IFNβ combination therapy will correlate with TRAIL expression and function remains to be determined. </jats:p>", "link": "https://journals.sagepub.com/doi/pdf/10.1191/1352458505ms1222oa", "published_date": "2005-12-01T00:00:00Z", "source": "SAGE Publications", "publisher": "SAGE Publications", "container_title": "Multiple Sclerosis Journal", "authors": [ { "author_id": 308061, "given_name": "N", "family_name": "Arbour", "ORCID": null, "country": null }, { "author_id": 308062, "given_name": "E", "family_name": "Rastikerdar", "ORCID": null, "country": null }, { "author_id": 308063, "given_name": "E", "family_name": "McCrea", "ORCID": null, "country": null }, { "author_id": 295349, "given_name": "Y", "family_name": "Lapierre", "ORCID": null, "country": null }, { "author_id": 287972, "given_name": "J", "family_name": "Dörr", "ORCID": null, "country": null }, { "author_id": 245829, "given_name": "A", "family_name": "Bar-Or", "ORCID": null, "country": null }, { "author_id": 308064, "given_name": "J P", "family_name": "Antel", "ORCID": null, "country": null } ], "relevant": null, "ml_prediction_gnb": false, "ml_prediction_lr": false, "ml_prediction_lsvc": false, "discovery_date": "2022-06-09T10:40:10.351612Z", "noun_phrases": [ "Upregulation", "TRAIL expression", "human T lymphocytes", "interferon b", " glatiramer acetate" ], "doi": "10.1191/1352458505ms1222oa", "access": "restricted", "takeaways": " We measured the in vivo and in vitro effects of interferon (IFN)b and glatiramer acetate (GA) on the expression of the regulatory molecule, tumor necrosis factor related apoptosis inducing ligand (TRAIL) in patients with multiple sclerosis . We confirmed the prior observation that TRAIL is enhanced on anti-CD3 activated T cells by the in vitro addition of IFNβ .", "categories": [] } ] }